Clinical trial · Observational
Registry Study - Whipple at the Splenic Artery
Whipple at the Splenic Artery - A Procedure for Ductal Adenocarcinoma of the Pancreas With Extensive Involvement of the Porto-Mesenteric Axis: A Registry Study
NCT01155882CI-TRIAL-00036642WATSAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine how effective Whipple at the Splenic Artery (WATSA).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whipple at the Splenic Artery (WATSA) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Whipple Surgery at the Splenic Artery
- description
- Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
- interventionNames
- Procedure: Whipple at the Splenic Artery (WATSA)
Primary outcomes (2)
- measure
- Effectivity of the Whipple at the Splenic Artery
- timeFrame
- By CT scan at 8 weeks post surgery
- description
- To determine how effective Whipple at the Splenic Artery (WATSA) is at resecting tumors with negative microscopic margins (R0) at the resection line on the pancreas and at the tangential posterior, uncinate, and venous margins.
- measure
- To determine range of morbidity and mortality
- timeFrame
- 30 day postoperative mortality
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Eligibility Criteria - Prospective Portion: * Patient must have diagnosis of ductal adenocarcinoma of head and/or neck of pancreas, ampullary adenocarcinoma, or pancreatic neuroendocrine tumor confirmed by tissue diagnosis. * Patient must be between 18 to 85 years of age. * Patient must be a candidate for the WATSA procedure or have had the WATSA surgery performed within 1 year. * Patient must be able to understand and willing to sign a written informed consent document. Eligibility Criteria - Retrospective Portion: Patient underwent WATSA procedure at our institution between 01/01/2009 and 12/31/2011.
References
Publications (0)
Data not yet available
No reference posted for this study.